KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO).

David Mocini, Stefania Angela Di Fusco, Edoardo Mocini, Lorenzo Maria Donini, Carlo Lavalle, Andrea Di Lenarda, Carmine Riccio, Pasquale Caldarola, Leonardo De Luca, Michele Massimo Gulizia, Fabrizio Oliva, Domenico Gabrielli, Furio Colivicchi

J Clin Med 10(18) 4185

PMID34575306
PMCIDPMC8468506
DOI10.3390/jcm10184185
发表日期2021-09-28
摘要

摘要

The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban (DOACs) offers some major advantages over warfarin and other vitamin K antagonists (VKAs). One advantage is the possibility to use a fixed dose in normal-weight patients, overweight patients and patients with obesity. However, the "one size fits all" strategy raised a concern regarding the possibility to undertreat patients with a high body mass index. No randomized controlled trials (RCTs) have ever compared VKAs and DOACs in this population. We analyzed data from the literature on DOAC pharmacokinetics and pharmacodynamics, results from the four pivotal phase III trials on non-valvular atrial fibrillation, retrospective observational studies and metanalyses. While we are aware of the limitation imposed by the absence of specific RCTs, we propose the position of the Italian Association of Hospital Cardiologists (ANMCO) on the use of DOACs in patients with obesity based on the existing evidence.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。